Mergers & acquisitions
Under the terms of the deal, Pfizer will pay $340 million up front with another $470 million in payments contingent on milestones for the development and commercialization of TA-46 for the treatment of achondroplasia.
With a $250 million cash down payment, Denmark’s H. Lundbeck A/S snapped up San Diego-based Abide Therapeutics to gain a novel discovery platform and a U.S.-based research hub.
Eisai Co., Ltd has bought out Purdue Pharma L.P.'s rights in the worldwide collaboration for the development and commercialization of lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of multiple sleep-wake disorders, including insomnia and irregular sleep-wake rhythm disorder (ISWRD) in patients with Alzheimer Disease.
UndergroundStocks.com, an elite wall street independent small cap media group with a history of bringing lucrative opportunities, Reports on Omni Health, Inc.
The company indicated it was dropping LY2606368, prexasertib, a CHK1 drug in Phase II, and LY3023414, a PI3k/mTOR inhibitor that was also in Phase II.
This is the second extension that has been filed, this time delaying it until June 3. The companies indicate it is because U.S. authorities are taking longer than expected to review the deal.
The project company Belina is running an innovative project in early phase and is developing a product for treatment of breast cancer.
Eur 140 m bridge loan was drawn to secure evotec’s value chain expansion by successful acquisition of aptuit in august 2017
Pharma and biotechs from across the globe share news, pipeline updates, with stories from Vetter, Atomwise, Tessa, GenSight, and more.
The combination of the two companies will create a leader in cell-based cancer immunotherapy, Kiadis said. It also further expands Kiadis’ toehold in the United States.
PRESS RELEASES